Compare Eli Lilly And Co (LLY) vs Unilever plc (UL) Price & Performance

Eli Lilly (LLY) trades at $1,176.69, down 1.01% on the day, amid a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 consensus. Revenue surged to $65.18B in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing growth prospects.

The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include elevated valuation multiples and competitive pressures in the pharmaceutical sector. With a consensus price target of $1,350, upside potential exists, but investors should weigh execution risks against the company's innovation pipeline.

Unilever (UL) trades at $61.98, up 1.64% with a bullish technical signal despite recent earnings misses. The company shows strong profitability with 18.32% net margin and 54.56% ROE, though revenue declined to $50.5B in 2025. Analyst sentiment is mixed with 24% buy ratings amid ongoing business restructuring including the planned McCormick food division sale.

UL offers defensive exposure with emerging market growth potential but faces execution risks from portfolio streamlining. The stock presents moderate valuation (P/E 21.59) with cash flow stability, though recent earnings underperformance and regulatory scrutiny on the McCormick deal warrant caution for near-term investors.